Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1623 1691 1693
This examiner grants 45% of resolved cases
Examiner Crews presents a challenging path in Art Unit 1623, with an allowance rate of 44.7% across 94 resolved cases. This suggests a rigorous examination process in Tech Center 1600. The median days to allowance of 1227 further highlights the difficulty, showing a long timeline. These metrics, based on 94 resolved cases, indicate that securing a patent requires both persistence and a high level of technical justification.
However, the interview lift of 70.3% is among the highest recorded. This suggests that for the 94 resolved cases, an interview was almost always necessary to achieve an allowance. Given the low 44.7% baseline allowance rate and the long 1227-day median pendency, an interview is an essential and highly effective tool for any applicant assigned to this examiner. The 70.3% lift is a clear signal that the examiner is extremely responsive to verbal arguments and collaborative problem-solving. Utilizing this tool is the most effective way to navigate the 1227-day timeline and improve the probability of success in this rigorous art unit.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18256401 | REDUCTION OF RANCIDITY OF VEGETABLE OILS | Final Rejection | DSM IP Assets B.V. |
| 18665849 | PHARMACEUTICAL COMPOSITION FOR TREATING COLORECTAL CANCER, INCLUDING TUMOR-TARGETED LIPOSOMES CONTAINING PLATYCODIN D2 | Non-Final OA | RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY |
| 18032149 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY | Non-Final OA | North Carolina State University |
| 17431462 | Methods for purifying bacterial polysaccharides | Final Rejection | Pfizer Inc. |
| 18109021 | CORONAVIRUS TREATMENT COMPOSITION AND METHOD | Final Rejection | University of Tennessee Research Foundation |
| 17415735 | NA+/K+ ATPASE INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF METASTASIS | Final Rejection | UNIVERSITÄT BASEL |
| 18561470 | PHARMACEUTICAL COMPOSITION COMPRISING HYALURONIC ACID COMPLEX FOR PREVENTION OR TREATMENT OF SKIN DISEASE | Final Rejection | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 17422638 | COMPOSITIONS AND METHODS FOR INDUCING OR SUPPLEMENTING SOCS3 TO ABROGATE TUMOR GROWTH AND PROLIFERATIVE RETINOPATHY | Final Rejection | Children's Medical Center Corporation |
| 18192291 | NUCLEOSIDES AND NUCLEOTIDES WITH 3' VINYL BLOCKING GROUP | Final Rejection | Illumina, Inc. |
| 17779706 | SYNTHESIS OF 3 -RNA OLIGONUCLEOTIDES | Final Rejection | ALNYLAM PHARMACEUTICALS, INC. |
| 17612056 | AMIDE-SUBSTITUTED IMIDAZO COMPOUNDS AS SELECTIVE INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASES | Non-Final OA | BEIGENE, LTD. |
| 17597878 | ANTICANCER AGENTS | Final Rejection | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
| 18039107 | IMMUNOTHERAPY FOR CANCER | Final Rejection | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOL |
| 18012694 | SAPONIN DERIVATIVES FOR USE IN MEDICINE | Final Rejection | SAPREME TECHNOLOGIES B.V. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy